药物发现和开发的基本原则 1336条(本栏目收费,不能显示细节,电话13136136841)
Animal models, disease states (Continued ) 0
isomorphic animal models, 312 312
knockout animal models, 45–47, 47f 47
neuroscience animal model 0
contextual fear conditioning model,317–318, 318f 318
elevated plus maze, 315–316, 316f 316
forced swimming test, 315, 315f 315
Morris water maze, 318–319, 319f 319
amyotrophic lateral sclerosis, SOD1-G93A mouse, 320–321, 321f 321
Parkinson’s disease, MPTP Model,321–323, 322f 322
novel object recognition test, 316–317,317f 317
number of animals, 314 314
oncology animal model, 335–336 336
genetically engineered mouse (GEM) 0
models, 338–339, 338f 338
mouse allograft tumor model, 337–338 338
Antagonists, 113f, 114, 151 151
calcium-sensing receptor, 280–281 281
GPCR’s natural ligand block, 177–178 178
postsynaptic nAChR, 121–122 122
YFP fluorescence, 170–171 171
Antihypertensive agents, 323, 325 325
Antiporters, 129–130, 130f 130
Automated uHTS system, 55–56, 56f 56
BACE inhibitors. See β-Secretase (BACE) 0
Basal activity, 113f, 114, 150f, 151 151